<< Back to News

New FDA Approval for DARZALEX®

Janssen Biotech, Inc., is pleased to inform you that the US Food and Drug Administration has recently approved DARZALEX® (daratumumab) for use in combination with bortezomib, melphalan, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

DARZALEX® is the first and only CD38-targeted monoclonal antibody approved as monotherapy and in combination with other therapies for the treatment of multiple myeloma across various lines of therapy.

To learn more about the recent approval of DARZALEX®, view the press release or visit www.darzalexhcp.com.